Takeaways: Kashiv BioSciences gets a key regulatory step for its XOLAIR (omalizumab) biosimilar, ADL-018. The market implication is a likely cost-reduction play in a high-value o...
Takeaways: Sunshine Biopharma’s approval for generic rivaroxaban (Xarelto) adds a high-volume, key anticoagulant to its Canadian portfolio and pairs with its existing generic apixaban to create ...
Takeaways: BeOne Medicines has cleared the key reimbursement hurdles in Canada for Tevimbra + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metastatic...
Takeaways: Quaebec’s reimbursement of Vanflyta is a pivotal step toward pan‑Canadian access for a high‑value, biomarker‑targeted AML therapy. Market-wise, public funding acr...
Takeaways: Vimy Pharma’s filing could position it as a domestic, lower-cost semaglutide supplier in Canada, which supports affordability and national supply resilience. The broader market ...
Takeaways: Novo Nordisk is defending branded Ozempic’s market share by narrowing the price gap with generic semaglutide for uninsured Canadians. That should help reduce switching to lower-cost a...
Takeaways: IHEEZO gives Apotex a differentiated, in‑clinic anesthetic that strengthens its positioning with Canadian ophthalmologists and complements its anti‑inflammatory an...
Takeaways: HArmonyCa with Lidocaine positions Allergan Aesthetics to capture more of Canada’s growing demand for longer-lasting, non-surgical facial rejuvenation by offering both immediate ...
Takeaways: Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market...
Takeaways MedExpress is adding another low-cost telehealth channel for generic semaglutide in Canada, which should increase competition among virtual clinics and make GLP‑1 access even easier fo...
